(NYSEMKT: LCTX) Lineage Cell Therapeutics's forecast annual revenue growth rate of -4.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12%.
Lineage Cell Therapeutics's revenue in 2026 is $10,836,000.On average, 8 Wall Street analysts forecast LCTX's revenue for 2026 to be $2,058,292,915, with the lowest LCTX revenue forecast at $692,590,144, and the highest LCTX revenue forecast at $5,443,333,567. On average, 9 Wall Street analysts forecast LCTX's revenue for 2027 to be $3,794,068,505, with the lowest LCTX revenue forecast at $1,338,636,611, and the highest LCTX revenue forecast at $7,020,000,611.
In 2027, LCTX is forecast to generate $1,717,309,893 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $5,046,447,542.